Context: Although current international guidelines recommend to avoid mineralocortcoid receptor antagonists in patients undergoing screening test for primary aldosteronism, a recent report suggested that mineralocorticoid receptor antagonist treatment can be continued without significant influence on screening results.
Objective: We aimed to evaluate the effect of mineralocorticoid receptor antagonists on the aldosterone to renin ratio in patients with primary aldosteronism.
Methods: We prospectively enrolled 121 patients with confirmed primary aldosteronism who started mineralocorticoid receptor antagonist (canrenone) treatment. Eighteen patients (11 with unilateral and 7 with bilateral primary aldosteronism) constituted the short-term study cohort and underwent aldosterone, renin, and potassium measurement after 2 and 8 weeks of canrenone therapy. The long-term cohort comprised 102 patients (16 with unilateral and 67 with bilateral primary aldosteronism, and 19 with undetermined subtype) who underwent hormonal and biochemical re-assessment after 2 to 12 months of canrenone therapy.
Results: Renin and potassium levels showed a significant increase, and the aldosterone to renin ratio displayed a significant reduction compared with baseline after both a short- and long-term treatment. These effects were progressively more evident with higher doses of canrenone and after longer periods of treatment. We demonstrated that canrenone exerted a deep impact on the diagnostic accuracy of the screening test for primary aldosteronism: the rate of false negative tests was raised to 16.7%, 38.9%, 54.5%, and 72.5% after 2 weeks, 8 weeks, 2 to 6 months, and 7 to 12 months of mineralocorticoid receptor antagonist treatment, respectively.
Conclusion: Mineralocorticoid receptor antagonists should be avoided in patients with hypertension before measurement of renin and aldosterone for screening of primary aldosteronism.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1210/clinem/dgab290 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Effects of Aldosterone on Hypertension-Associated Kidney Injury in a Tg-hAS Mouse Model.
Biology (Basel)
December 2024
Department of Neurology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Hypertension remains a global health challenge due to its high prevalence and association with premature morbidity and mortality. Aldosterone, a mineralocorticoid hormone, and its receptor, the mineralocorticoid receptor (MR), are highly implicated in hypertension pathogenesis. Aldosterone synthase is the sole enzyme responsible for producing aldosterone in humans.
View Article and Find Full Text PDFAn In Silico Investigation of the Pathogenic G151R G Protein-Gated Inwardly Rectifying K Channel 4 Variant to Identify Small Molecule Modulators.
Biology (Basel)
November 2024
Epigenomic Medicine Laboratory at prospED Polytechnic, Melbourne, VIC 3053, Australia.
Primary aldosteronism is characterised by the excessive production of aldosterone, which is a key regulator of salt metabolism, and is the most common cause of secondary hypertension. Studies have investigated the association between primary aldosteronism and genetic alterations, with pathogenic mutations being identified. This includes a glycine-to-arginine substitution at position 151 (G151R) of the G protein-activated inward rectifier potassium (K) channel 4 (GIRK4), which is encoded by the gene.
View Article and Find Full Text PDFTargeting cholesterol-dependent adrenal steroidogenesis for management of primary aldosteronism.
Trends Endocrinol Metab
January 2025
Department of Hypertension and Endocrinology, Center for Hypertension and Metabolic Diseases, Daping Hospital, Army Medical University, Chongqing Institute of Hypertension, Chongqing, China; Chongqing Institute for Brain and Intelligence, Chongqing, China. Electronic address:
Primary aldosteronism (PA) is a common, salt-sensitive form of endocrine hypertension. Compared with essential hypertension (EH), PA is more susceptible to cardiorenal complications and metabolic risks. However, PA has a low screening rate and a poor response to mineralocorticoid receptor antagonists (MRAs).
View Article and Find Full Text PDFHypokalemia-Induced Rhabdomyolysis Secondary to Adrenal Adenoma: A Case Report.
Cureus
December 2024
Pulmonary and Critical Care Medicine, Icahn School of Medicine at Mount Sinai/New York City Health + Hospitals - Queens, New York City, USA.
Adrenal adenoma, which leads to increased production of the hormone aldosterone, commonly presents as hypertension and hypokalemia. Rhabdomyolysis as a result of hypokalemia secondary to primary hyperaldosteronism is a rare but important complication with only a few reported cases. Low potassium levels can disrupt the regulation of arteriolar musculature, leading to reduced blood flow to skeletal muscles.
View Article and Find Full Text PDFLiquorice-induced pseudohyperaldosteronism: a rare cause for severe hypertension.
BMJ Case Rep
January 2025
SUT Hospital, Thiruvananthapuram, Kerala, India.
This case report describes an adult man in his 50s with a history of type 2 diabetes and previously well-controlled hypertension, who presented with uncontrolled hypertension, muscle weakness and fatigue. Biochemical testing revealed hypokalaemia. There was no evidence of renal/renovascular disease.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!